Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of Tislelizumab combined with platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB/C-IV non-squamous non-small cell lung cancer. This study aims to provide more treatment options for patients with locally advanced non-small cell lung cancer.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Age 18-75 years old, gender is not limited;
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
• Patients with stage IIIB/C-IV non-squamous non-small cell lung cancer confirmed by cytology or histology;
• Patients who have not received prior systemic therapy;
Locations
Other Locations
China
Zibo Municipal Hospital
RECRUITING
Zibo
Contact Information
Primary
Qiang Wang
18953316759@163.com
+8618953316759
Time Frame
Start Date: 2024-01-13
Estimated Completion Date: 2028-12-10
Participants
Target number of participants: 20
Treatments
Experimental: treatment arm
For patients with driver gene-negative stage IIIB/C-IV non-squamous non-small cell lung cancer, after 4 cycles of Tislelizumab combined with platinum-based doublet chemotherapy, if the tumor efficacy evaluation reaches SD, PR, or CR, radiotherapy will be administered to the tumor lesions combined withTislelizumab. After that, Tislelizumab maintenance therapy will be continued.
Related Therapeutic Areas
Sponsors
Leads: Zibo Municipal Hospital